PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Perjeta

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**
Member/Subscriber Number:	Fax: Phone:
Date of Birth:	Office Contact:
Group Number:	NPI: State Lic ID:
Address: Address:	
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. For what diagnosis is this drug being prescribed (pick one)?

☐ Metastatic breast cancer

☐ Neoadjuvant treatment of locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)

☐ Other

Q2. Will Perjeta be office-administered using provider stock (buy and bill)?

☐ Yes ☐ No

Q3. Please provide the ICD diagnosis code for above condition.

Q4. Is this drug being prescribed by an oncologist?

☐ Yes ☐ No

Q5. Is the patient HER2-positive?

☐ Yes ☐ No

Q6. Will this drug be used in combination with Herceptin (trastuzumab)?

☐ Yes ☐ No

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Perjeta

Phone: 800-728-7947 **Fax back to: 866-880-4532**

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	**Prescriber Name:** **Supervising Physician:**

Q7. Will this drug be used in combination with taxane therapy?

☐ Yes ☐ No

Q8. Has the patient received prior anti-HER2 therapy or chemotherapy for metastatic disease?

☐ Yes ☐ No

Q9. Additional Comments:

Prescriber Signature _____ Date _____

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.